WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--May 16, 2006--Endocyte Inc., today (Tuesday, May 16) announced that a patent has been issued for a proprietary technology designed to target the body’s immune system to cancer cells. The U.S. Patent and Trademark Office has issued U.S. Patent Number 7,033,594 for “Method of Treatment Using Ligand-Immunogen Conjugates,” a technology developed by researchers at the company and Purdue University to improve tumor cell targeting in immunotherapy. The technology is designed to specifically enhance the ability of the immune system to detect and respond to folate receptor-positive cancers, potentially representing a platform for the development of immunotherapeutic products to treat a range of human disease conditions.
